Medulloblastoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Medulloblastoma

Medulloblastoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Medulloblastoma is a cancerous tumor—also called cerebellar primitive neuroectodermal tumor (PNET)- that starts in the region of the brain at the base of the skull, called the posterior fossa. Tumors tend to spread to other parts of the brain and to the spinal cord. There’s a small percent of childhood medulloblastomas that are related to gene changes that can be passed down through families. There’s no known cause for adults diagnosed with medulloblastomas.

The 4 molecular subgroups currently recognised in the WHO classification have been named WNT, SHH, Group 3, and Group 4.

Medulloblastoma - wingless (WNT) subgroup tumours are the least common medulloblastoma subgroup and have by far the best prognosis. They are usually seen in children and, to a lesser degree, adults. They typically arise from the region surrounding the foramen of Luschka and middle cerebellar peduncle.

WNT tumours account for only 11% of all medulloblastomas, and have, unlike group 3 and 4 tumours, no particular predilection for males, with ~1:1 male to female ratio

Medulloblastoma - sonic hedgehog (SHH) subgroup tumours are malignant tumours of the central nervous system. They are the second most common medulloblastoma subgroup (after group 4) and are approximately as common as group 3. They are found most commonly in adults and infants, but infrequently in children. Although they can arise from the vermis of the cerebellum, as is typical for group 3 and 4, they are most frequently located laterally within the cerebellar hemispheres.

SHH subgroup tumours account for approximately 27% of all medulloblastomas, and, unlike group 3 and 4, have no particular predilection for males, with a ~1:1 male to female ratio

Medulloblastoma - group 3 tumours are malignant tumours of the central nervous system, and one of the most common paediatric tumours. They typically arise from the vermis of the cerebellum and present in childhood and infancy. They have the worst prognosis of all medulloblastoma subgroups.

Group 3 tumours account for approximately 27% of all medulloblastomas, and have a predilection for males, with a 2:1 male to female ratio.

Medulloblastoma - group 4 tumours are malignant tumours of the central nervous system, and one of the most common paediatric tumours. They are the most common medulloblastoma subgroup (followed by group 3, SHH, and WNT), and typically arise from the vermis of the cerebellum.

Group 4 tumours account for approximately 34-40% of all medulloblastomas, and have a predilection for males, with a 2:1 male to female ratio

Epidemiology- Overall medulloblastomas account for 12-25 % of all paediatric CNS tumours, and 30-40% of paediatric posterior fossa tumours 1,7. They are also seen in adults but only account for 0.4-1.0% of adult brain tumours 1. Since there are many more adults than children, 14-30% of all medulloblastomas are found in adults.

Competitive landscape of Medulloblastoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Medulloblastoma Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Medulloblastoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Medulloblastoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        177Lu-DTPA-omburtamab        Y-mAbs Therapeutics        Phase 2

2        LDE225        Novartis Pharmaceuticals        Phase 2

3        AloCELYVIR        Apices Soluciones S.L.        Phase 2

4        TB-403        Oncurious NV        Phase 1

5        Nifurtimox        Bayer        Phase 2

6        TPI 287        Cortice Biosciences, Inc.        Phase 1

7        Cyclophosphamide        Genentech, Inc.        Phase 2

8        Prexasertib        Eli Lilly and Company        Phase 1

9        Pomalidomide        Celgene        Phase 2

10        NKTR-214        Nektar Therapeutics        Phase 2

11        VAL-413        Valent Technologies, Inc.        Phase 1

12        ZSP1602        Guangdong Zhongsheng Pharmaceutical Co., Ltd.        Phase 1"